JP2024542682A - 治療 - Google Patents

治療 Download PDF

Info

Publication number
JP2024542682A
JP2024542682A JP2024532418A JP2024532418A JP2024542682A JP 2024542682 A JP2024542682 A JP 2024542682A JP 2024532418 A JP2024532418 A JP 2024532418A JP 2024532418 A JP2024532418 A JP 2024532418A JP 2024542682 A JP2024542682 A JP 2024542682A
Authority
JP
Japan
Prior art keywords
dose
tcr
range
seq
fusion molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532418A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542682A5 (https=
JPWO2023099622A5 (https=
Inventor
モハメド ダール
シャノン マーシャル
シャード アブドゥッラー
Original Assignee
イムノコア リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イムノコア リミテッド filed Critical イムノコア リミテッド
Publication of JP2024542682A publication Critical patent/JP2024542682A/ja
Publication of JP2024542682A5 publication Critical patent/JP2024542682A5/ja
Publication of JPWO2023099622A5 publication Critical patent/JPWO2023099622A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024532418A 2021-12-01 2022-11-30 治療 Pending JP2024542682A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163285044P 2021-12-01 2021-12-01
US63/285,044 2021-12-01
US202263374222P 2022-08-31 2022-08-31
US63/374,222 2022-08-31
PCT/EP2022/083952 WO2023099622A1 (en) 2021-12-01 2022-11-30 Treatment

Publications (3)

Publication Number Publication Date
JP2024542682A true JP2024542682A (ja) 2024-11-15
JP2024542682A5 JP2024542682A5 (https=) 2025-12-08
JPWO2023099622A5 JPWO2023099622A5 (https=) 2025-12-08

Family

ID=84688213

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532418A Pending JP2024542682A (ja) 2021-12-01 2022-11-30 治療

Country Status (9)

Country Link
US (1) US20250333504A1 (https=)
EP (1) EP4441096A1 (https=)
JP (1) JP2024542682A (https=)
KR (1) KR20240114759A (https=)
AU (1) AU2022402322A1 (https=)
IL (1) IL312981A (https=)
MX (1) MX2024006799A (https=)
TW (1) TW202330589A (https=)
WO (1) WO2023099622A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202519257A (zh) 2023-08-01 2025-05-16 英商英美偌科有限公司 治療皮膚黑色素瘤之方法
TW202544042A (zh) 2024-03-13 2025-11-16 英商英美偌科有限公司 治療prame陽性癌症之方法
WO2025224692A1 (en) 2024-04-25 2025-10-30 Immunocore Limited Method of treating cancer using a gene expression signature

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002321581C1 (en) 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
WO2017208018A1 (en) * 2016-06-02 2017-12-07 Immunocore Limited Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
GB201709866D0 (en) 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors

Also Published As

Publication number Publication date
TW202330589A (zh) 2023-08-01
EP4441096A1 (en) 2024-10-09
WO2023099622A1 (en) 2023-06-08
KR20240114759A (ko) 2024-07-24
US20250333504A1 (en) 2025-10-30
AU2022402322A1 (en) 2024-06-20
MX2024006799A (es) 2024-08-22
IL312981A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
JP2024542682A (ja) 治療
ES2951650T3 (es) Uso de un anticuerpo anti-PD-1 junto con un anticuerpo anti-CD30 en el tratamiento del linfoma
TW202227132A (zh) 使用抗ｐｄ－１抗體與抗ｃｔｌａ－４抗體之組合以治療肺癌
US20240301027A1 (en) Treatment of mage-a4 positive cancer
JP2026021459A (ja) 黒色腫の処置のためのｌａｇ－３アンタゴニスト
US20250346670A1 (en) Methods of treating cancer by administering a neoadjuvant pd-1 inhibitor
WO2023081718A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
KR20230093282A (ko) 폐암에 대한 lag-3 길항제 요법
TWI899236B (zh) 通過投予pd-1抑制劑治療子宮頸癌的方法
CN118510808A (zh) 治疗
CA3239837A1 (en) Treatment
CN117043193A (zh) 通过施用新辅助pd-1抑制剂治疗癌症的方法
JP2023540217A (ja) Ｐｄ－１阻害剤を投与することによりがんを処置する方法
IL302321A (en) IL-2/IL-15RBY agonist for the treatment of squamous cell carcinoma
WO2025027557A1 (en) Method of treating cutaneous melanoma
JP2025540235A (ja) がんの処置および予防のための組合せ
JP2026514110A (ja) がんの処置および予防のための組合せ
JP2025530186A (ja) 胃食道がんの治療において使用するための改変ｔ細胞
WO2025068803A1 (en) Therapeutic combinations comprising anti-steap2 chimeric antigen receptor t cells
HK40098919A (zh) 用pd-1轴结合拮抗剂和rna疫苗诱导新表位特异性t细胞的方法
CA3167436A1 (en) Method of treatment of cancer or tumour
IL302313A (en) IL-2/IL-15RBY agonist for the treatment of non-melanoma skin cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251128